Table 2. In Vivo Antimalarial Activity of Selected 4-Aminoquinoline-pyrimidine Hybrids in the P. berghei–Mouse Malaria Model.
| % suppression
in parasitemiaa |
||||||
|---|---|---|---|---|---|---|
| treatment (po) | dose (mg/kg × no. of days postinfection) | day 5 | day 7 | survivalb | MSTc | cured |
| vehicle | NA × 4 | 0/5 | 15.2 | 0/5 | ||
| CQ | 100 × 3 | 100.0 | 100.0 | 5/5 | 28 | 0/5 |
| 8i | 3.3 × 3 | 23.5 | 35.2 | 1/5 | 19.2 | 0/5 |
| 8i | 10 × 3 | 97.0 | 2.0 | 0/5 | 21.4 | 0/5 |
| 8i | 30 × 3 | 100.0 | 100.0 | 5/5 | 28 | 4/5 |
| 8m | 3.3 × 3 | 20.1 | 19.1 | 0/5 | 20.2 | 0/5 |
| 8m | 10 × 3 | 73.9 | 27.1 | 0/5 | 15.2 | 0/5 |
| 8m | 30 × 3 | 100.0 | 100.0 | 4/5 | 27.2 | 1/5 |
a
The % suppression in parasitemia is calculated by considering the mean parasitemia in the vehicle control as 100%. Parasitemia suppression <80% is considered as nonsignificant.
b
Number of animals that survived on day 28/total animals in the group (the day of the death postinfection).
c
MST, mean survival time (days).
d
Number of mice without parasitemia (cured) until day 28 postinfection.